{"id":"prednisone-continuation","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL15720","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone acts as a glucocorticoid receptor agonist, inhibiting the production and release of pro-inflammatory cytokines and reducing immune cell activation. It decreases capillary permeability, stabilizes lysosomal membranes, and suppresses both humoral and cell-mediated immune responses. This broad immunosuppressive and anti-inflammatory action makes it effective across multiple therapeutic areas.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:17.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders"},{"name":"Allergic reactions"},{"name":"Certain malignancies (as adjunctive therapy)"},{"name":"Adrenal insufficiency"},{"name":"Respiratory conditions with inflammation"}]},"trialDetails":[{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT07209059","phase":"PHASE2","title":"PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2025-07-29","conditions":"Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT02670707","phase":"PHASE3","title":"Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2016-03-07","conditions":"Langerhans Cell Histiocytosis","enrollment":124},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT00488605","phase":"PHASE3","title":"H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2023-08-01","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT04773366","phase":"PHASE3","title":"A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2018-07-01","conditions":"Langerhans Cell Histiocytosis","enrollment":200},{"nctId":"NCT01681433","phase":"PHASE2","title":"OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone","status":"TERMINATED","sponsor":"Costantine Albany","startDate":"2012-12","conditions":"Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA","enrollment":72},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT02284464","phase":"PHASE4","title":"Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2015-02","conditions":"Other Complication of Kidney Transplant, Renal Transplant Rejection","enrollment":230},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT00973752","phase":"PHASE2","title":"Treatment of Older Adults With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT01230983","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":"Cardiac Toxicity, Leukemia, Lymphoma","enrollment":573},{"nctId":"NCT00165178","phase":"PHASE3","title":"Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2000-09","conditions":"Acute Lymphoblastic Leukemia","enrollment":498},{"nctId":"NCT00408213","phase":"PHASE3","title":"A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Myasthenia Gravis Generalised","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":172,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prednisone continuation","genericName":"Prednisone continuation","companyName":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","companyId":"fundaci-n-p-blica-andaluza-para-la-investigaci-n-de-m-laga-en-biomedicina-y-salu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders, Allergic reactions, Certain malignancies (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}